Wedbush Analysts Lift Earnings Estimates for Adicet Bio

Adicet Bio, Inc. (NASDAQ:ACET) – Research analysts at Wedbush lifted their Q3 2025 earnings estimates for shares of Adicet Bio in a note issued to investors on Tuesday, May 6th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.32) per share for the quarter, up from their prior estimate of ($0.33). The consensus estimate for Adicet Bio’s current full-year earnings is ($1.39) per share. Wedbush also issued estimates for Adicet Bio’s FY2025 earnings at ($1.22) EPS, FY2026 earnings at ($1.11) EPS, FY2027 earnings at ($1.07) EPS, FY2028 earnings at ($1.04) EPS and FY2029 earnings at ($1.05) EPS.

Adicet Bio (NASDAQ:ACET) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.03.

ACET has been the subject of a number of other reports. JMP Securities reaffirmed a “market perform” rating on shares of Adicet Bio in a research note on Thursday, February 6th. HC Wainwright restated a “neutral” rating on shares of Adicet Bio in a report on Friday, March 7th. Guggenheim reiterated a “buy” rating and issued a $7.00 target price on shares of Adicet Bio in a report on Friday, March 21st. Finally, StockNews.com raised shares of Adicet Bio from a “sell” rating to a “hold” rating in a research report on Monday, April 28th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.50.

Adicet Bio Trading Up 28.1 %

NASDAQ:ACET opened at $0.61 on Friday. Adicet Bio has a 1-year low of $0.45 and a 1-year high of $1.71. The firm has a market capitalization of $50.67 million, a price-to-earnings ratio of -0.36 and a beta of 1.76. The business’s 50-day moving average price is $0.68 and its two-hundred day moving average price is $0.90.

Hedge Funds Weigh In On Adicet Bio

Several institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. raised its holdings in Adicet Bio by 10,321.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 80,353 shares of the company’s stock worth $116,000 after buying an additional 79,582 shares during the period. Geode Capital Management LLC increased its position in shares of Adicet Bio by 14.5% during the third quarter. Geode Capital Management LLC now owns 768,566 shares of the company’s stock worth $1,107,000 after acquiring an additional 97,567 shares in the last quarter. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Adicet Bio during the fourth quarter worth $931,000. Norges Bank bought a new stake in Adicet Bio in the 4th quarter valued at $413,000. Finally, Virtu Financial LLC acquired a new position in Adicet Bio in the 4th quarter worth $29,000. Institutional investors own 83.89% of the company’s stock.

About Adicet Bio

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.